Lantern Pharma to Host Q3 2025 Results Webcast, Highlight AI Oncology Platform Progress

Lantern Pharma (NASDAQ: LTRN) announced it will host a webcast on November 13, 2025, to review third-quarter operating and financial results and provide updates on its artificial intelligence platform development. The event, scheduled for 9 a.m. ET, will feature President and CEO Panna Sharma alongside other management team members discussing quarterly performance, clinical trial progress, and upcoming milestones for the company's AI and machine learning initiatives.

The company's RADR platform represents a significant advancement in oncology drug development, leveraging over 200 billion oncology-focused data points and more than 200 machine learning algorithms. This technology addresses critical challenges in cancer treatment discovery by potentially reducing costs and accelerating development timelines. The platform's ability to process massive datasets and identify promising therapeutic candidates could revolutionize how cancer drugs are developed and brought to market.

Lantern Pharma's growing pipeline includes multiple clinical programs, with a Phase 2 clinical program and several Phase 1 trials currently underway. The company's therapies span both solid tumors and blood cancers, including an antibody-drug conjugate program. This diverse approach to oncology treatment development demonstrates the versatility of the RADR platform in addressing various cancer types and treatment modalities.

The company estimates its AI-driven pipeline of innovative product candidates has a combined annual market potential exceeding $15 billion. This substantial market opportunity underscores the financial significance of successful AI implementation in drug development. More importantly, these therapies have the potential to provide life-changing treatments to hundreds of thousands of cancer patients worldwide, addressing unmet medical needs across multiple cancer indications.

For investors and industry observers seeking additional information, the company maintains a newsroom at https://ibn.fm/LTRN where updates and developments are regularly posted. The upcoming webcast represents a crucial opportunity for stakeholders to assess the company's progress in leveraging artificial intelligence to transform oncology drug discovery and development.

The integration of AI technology in pharmaceutical development represents a paradigm shift in how new treatments are discovered and brought to patients. Lantern Pharma's approach could potentially reduce the traditional billion-dollar costs and decade-long timelines associated with drug development, making innovative cancer therapies more accessible and affordable. As the company continues to advance its clinical programs and refine its AI platform, the broader implications for cancer treatment and pharmaceutical innovation remain substantial for both patients and the healthcare industry.